DocGo, Inc. (DCGO)

NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-10-23

$0.27+0.44%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge DocGo, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	80.28M
EPS	—	-0.07
FY 2026 · Annual
Revenue	$300M–$315M	306.5M
Revenue (midpoint)	$7.5M	—
EPS	—	-0.508
FY 2027 · Annual
Revenue	—	325.77M
EPS	—	-0.27

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Adjusted EBITDA loss narrows to no worse than $10 million in 2026	The company plans to cut its adjusted EBITDA loss to $5 million.	Broken	Adjusted EBITDA loss exceeds $10 million in 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Adjusted EBITDA guidance for 2026 worsened from a loss of $5-$10 million in 2026-Q1 to a loss of $17-$22 million in 2026-Q2, reflecting margin pressures from hiring and fuel costs. Management still expects to achieve adjusted EBITDA profitability in the back half of 2026, indicating ongoing focus but mixed near-term delivery. Delivery assessment Oct 24, 2026
Resolve Nasdaq listing compliance issues	A supporting condition in DocGo, Inc.'s published investment case. The stated target is Compliance maintained through 2026.	Intact	Nasdaq delisting or failure to meet listing requirements	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q2. Management disclosed Nasdaq granted an extension of 180 days to regain compliance with the minimum bid price rule, until January 25, 2027. This regulatory priority is ongoing with no financial impact reported yet. Delivery assessment Oct 24, 2026
Full-year 2026 revenue reaches at least $300 million	A primary condition in DocGo, Inc.'s published investment case. The stated target is >=300 million USD.	Intact	Full-year 2026 revenue falls below $300 million	Revenue: $73.425M FY2026-Q2; GAAP. Published target: >=300 million USD. Target period is not explicitly aligned with this observation. Source published Aug 17, 202673,424,719 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 34f20458-512e-45ba-90c4-6c69d3c73c09. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management increased full-year 2026 revenue guidance from $290-$310 million in 2026-Q1 to $300-$315 million, then narrowed it to $305-$310 million in 2026-Q2. This reflects strong demand and organic growth in virtual care and mobile phlebotomy, consistent with management's stated growth focus. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	2 / 4
2026-07-25	Unavailable	$325,265,840	2 / 5
2026-07-26	Unavailable	Unavailable	2 / 4
2026-07-27	Unavailable	$325,265,840	2 / 5
2026-07-28	Unavailable	$325,265,840	2 / 5
2026-07-29	Unavailable	Unavailable	2 / 4
2026-07-30	Unavailable	$325,265,840	2 / 5
2026-07-31	Unavailable	$325,265,840	2 / 5
2026-08-01	Unavailable	Unavailable	2 / 4
2026-08-02	Unavailable	$325,265,840	2 / 5
2026-08-03	Unavailable	Unavailable	2 / 4
2026-08-04	Unavailable	Unavailable	2 / 4
2026-08-05	Unavailable	$325,265,840	2 / 5
2026-08-06	Unavailable	$325,265,840	2 / 5
2026-08-07	Unavailable	Unavailable	2 / 4
2026-08-08	Unavailable	$325,265,840	2 / 5
2026-08-09	Unavailable	$325,265,840	2 / 5
2026-08-10	Unavailable	Unavailable	2 / 4
2026-08-11	Unavailable	$325,265,840	2 / 5
2026-08-12	Unavailable	Unavailable	2 / 4
2026-08-13	Unavailable	Unavailable	2 / 4
2026-08-14	Unavailable	Unavailable	2 / 4
2026-08-15	Unavailable	Unavailable	2 / 4
2026-08-16	Unavailable	Unavailable	2 / 4
2026-08-17	Unavailable	Unavailable	2 / 4
2026-08-18	Unavailable	Unavailable	2 / 4
2026-08-19	Unavailable	Unavailable	2 / 4
2026-08-20	Unavailable	Unavailable	2 / 4
2026-08-21	Unavailable	Unavailable	2 / 4
2026-08-22	Unavailable	Unavailable	2 / 4
2026-08-23	Unavailable	Unavailable	2 / 4
2026-08-24	Unavailable	Unavailable	2 / 4
2026-08-25	Unavailable	Unavailable	2 / 4
2026-08-26	Unavailable	Unavailable	2 / 4
2026-08-27	Unavailable	Unavailable	2 / 4
2026-08-28	Unavailable	Unavailable	2 / 4
2026-08-29	Unavailable	Unavailable	2 / 4
2026-08-30	Unavailable	Unavailable	2 / 4
2026-08-31	Unavailable	Unavailable	2 / 4
2026-09-01	Unavailable	Unavailable	2 / 4
2026-09-02	Unavailable	Unavailable	2 / 4
2026-09-03	Unavailable	Unavailable	2 / 4
2026-09-04	Unavailable	Unavailable	2 / 4
2026-09-05	Unavailable	Unavailable	2 / 4
2026-09-06	Unavailable	Unavailable	2 / 4
2026-09-07	Unavailable	Unavailable	2 / 4
2026-09-08	Unavailable	Unavailable	2 / 4
2026-09-09	Unavailable	Unavailable	2 / 4
2026-09-10	Unavailable	Unavailable	2 / 4
2026-09-11	Unavailable	Unavailable	2 / 4
2026-09-12	Unavailable	Unavailable	2 / 4
2026-09-13	Unavailable	Unavailable	2 / 4
2026-09-14	Unavailable	Unavailable	2 / 4
2026-09-15	Unavailable	Unavailable	2 / 4
2026-09-16	Unavailable	Unavailable	2 / 4
2026-09-17	Unavailable	Unavailable	2 / 4
2026-09-18	Unavailable	Unavailable	2 / 4
2026-09-19	Unavailable	Unavailable	2 / 4
2026-09-20	Unavailable	Unavailable	2 / 4
2026-09-21	Unavailable	Unavailable	2 / 4
2026-09-22	Unavailable	Unavailable	2 / 4
2026-09-23	Unavailable	Unavailable	2 / 4
2026-09-24	Unavailable	Unavailable	2 / 4
2026-09-25	Unavailable	Unavailable	2 / 4
2026-09-26	Unavailable	Unavailable	2 / 4
2026-09-27	Unavailable	Unavailable	2 / 4
2026-09-28	Unavailable	Unavailable	2 / 4
2026-09-29	Unavailable	Unavailable	2 / 4
2026-09-30	Unavailable	Unavailable	2 / 4
2026-10-01	Unavailable	Unavailable	2 / 4
2026-10-02	Unavailable	Unavailable	2 / 4
2026-10-03	Unavailable	Unavailable	2 / 4
2026-10-04	Unavailable	Unavailable	2 / 4
2026-10-05	Unavailable	Unavailable	2 / 4
2026-10-06	Unavailable	Unavailable	2 / 4
2026-10-07	Unavailable	Unavailable	2 / 4
2026-10-08	Unavailable	Unavailable	2 / 4
2026-10-09	Unavailable	Unavailable	2 / 4
2026-10-10	Unavailable	Unavailable	2 / 4
2026-10-11	Unavailable	Unavailable	2 / 4
2026-10-12	Unavailable	Unavailable	2 / 4
2026-10-13	Unavailable	Unavailable	2 / 4
2026-10-14	Unavailable	Unavailable	2 / 4
2026-10-15	Unavailable	Unavailable	2 / 4
2026-10-16	Unavailable	Unavailable	2 / 4
2026-10-17	Unavailable	Unavailable	2 / 4
2026-10-18	Unavailable	Unavailable	2 / 4
2026-10-19	Unavailable	Unavailable	2 / 4
2026-10-20	Unavailable	Unavailable	2 / 4
2026-10-21	Unavailable	Unavailable	2 / 4
2026-10-22	Unavailable	Unavailable	2 / 4
2026-10-23	Unavailable	Unavailable	2 / 4
2026-10-24	Unavailable	Unavailable	2 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	3	3
2026-06-01	2	3
2026-07-01	2	3
2026-08-01	2	3
2026-09-01	2	3
2026-10-01	2	3

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Adjusted EBITDA loss narrows to no worse than $10 million in 2026Published status: Broken
Resolve Nasdaq listing compliance issuesQualitative condition
Full-year 2026 revenue reaches at least $300 millionRevenue: $73.425M

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.9%Typical daily move · historical

Downside history

-79.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

DocGo, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk growth business, not yet a proven profitable compounder. The multi-year view is intact, but execution is mixed: revenue guidance has risen while the expected adjusted EBITDA loss has widened.

What's priced into DocGo, Inc.

The valuation model points to DCGO as cheap versus peers, but confidence in that reading is low. The expectations gap is negative, suggesting the market’s assumptions are not clearly demanding, while the priced-in assessment calls the setup justified and finds little fragility.

What the fundamentals likely do

Near term, higher 2026 revenue guidance reflects strong demand and growth in virtual care and mobile phlebotomy. Profitability is less certain: adjusted EBITDA loss guidance worsened, though management still expects profitability in the back half of 2026. Recent quarterly misses and the elevated risk of another miss add uncertainty.

What DocGo, Inc. hinges on

The multi-year thesis depends on revenue growth translating into better margins and on management delivering its profitability goal. A guidance cut or further weakening in jobs data would weigh on the near-term setup, while continued strength from healthcare peers could support sector momentum. The Hicuity acquisition and the recent capital-allocation announcements are additional factors to monitor, but the evidence on their effects is limited.